ASX Announcement: 5 November 2026 (Melbourne, Australia)
Optiscan Imaging Ltd (ASX: OIL)

Optiscan Strengthens Board with Appointment of Russell Low

HIGHLIGHTS

- Mr Russell Low, President and Singapore Country Head of the Clermont Group, appointed Non-Executive Director as Clermont's nominee
- Mr Low succeeds Mr Sean Gardiner as Clermont's nominee, whose resignation from the Board is effective today
- Mr Low brings senior governance and transformation experience, including as former Executive Chairman of Hoan My Medical Corporation, Vietnam's largest private hospital network
- The appointment reinforces the continued support of cornerstone shareholder the Clermont Group as Optiscan advances its U.S. commercial rollout

Optiscan Imaging Limited (ASX: OIL) ('**Optiscan**' or the '**Company**') is pleased to announce the appointment of Mr Russell Low as a Non-Executive Director. Mr Low brings extensive international healthcare leadership, governance and portfolio oversight experience to the Board as Optiscan advances its U.S. commercial rollout and next phase of growth.

Mr Low joins the Board as the Clermont Group's nominee, succeeding Mr Sean Gardiner, whose resignation from the Board is effective today. The Clermont Group holds its investment in Optiscan through Orchid Capital Investments Pte Ltd, which has exercised its contractual right to nominate Mr Low to the Board pursuant to clause 7.1 of the Subscription Agreement between Optiscan and Orchid dated 21 September 2020.

EXPERIENCE ALIGNED TO OPTISCAN'S GROWTH STRATEGY

Mr Low is President and Singapore Country Head of the Clermont Group, a Singapore-headquartered international business group founded by New Zealand-born entrepreneur Richard Chandler. Clermont builds industry-leading businesses across healthcare, financial services and energy, employs more than 10,000 people globally, and is a major shareholder in Optiscan.

At Clermont, Mr Low leads group-wide governance, organisational development and portfolio oversight. He brings direct experience in leading and transforming large healthcare organisations. From 2019 to 2021 he was Executive Chairman of Hoan My Medical Corporation, Vietnam's largest private hospital

network of 15 hospitals, where he led an organisation-wide restructuring and steered the business through the COVID-19 pandemic. He also served on the board of The Medical City in the Philippines from 2018 to 2022.

A lawyer by training, Mr Low served in the Singapore Supreme Court and the Attorney-General's Chambers before joining Clermont. He graduated as University Valedictorian from Singapore Management University with degrees in law and business management, and holds a Master of Public Administration from Columbia University and a Master of Public Policy from the Lee Kuan Yew School of Public Policy.

CHAIR COMMENT

Optiscan Non-Executive Chair, Mr Robert Cooke, said:

"The Board welcomes Russell as the Clermont Group's nominee. The Clermont Group is a long-standing cornerstone shareholder of Optiscan, and Russell's appointment reflects its continued commitment to the Company as we enter our next phase of commercial growth and expansion. Russell brings deep experience in healthcare governance, organisational transformation and international portfolio oversight. His appointment strengthens the Board's governance capability and broadens our strategic network as we execute our U.S. commercial rollout."

"On behalf of the Board, I thank Mr Sean Gardiner for his contribution to Optiscan and wish him every success in his future endeavours. Sean brought financial discipline and strong commercial judgement to the Board, helping to position Optiscan for its next phase of growth."

– ends –

This announcement has been authorised for release by the Board of Optiscan.

For further information, please contact:

Shareholder & General Enquiries
Optiscan Imaging Ltd
Dr Camile Farah
T: +61 3 9538 3333
E: ceo@optiscan.com

Media & Investor Enquiries
The Capital Network
Julia Maguire
T: +61 2 7257 7338
E: julia@thecapitalnetwork.com.au

About Optiscan

Optiscan Imaging Ltd (ASX: OIL) is a commercial stage medical technology company creating a suite of digital pathology and precision surgery hardware and software solutions that enable live optical biopsy for life sciences, diagnostic and surgical applications. Optiscan pioneered the development and manufacturing of miniaturised digital

endomicroscopes with spatial resolution more than 1000x that of medical CT and MRI.

Using a revolutionary "tissue contact" method, Optiscan's patented technology produces super high-resolution digital pathology images for cancer diagnosis and surgical treatment, to unlock real-time insights during surgery, diagnostics, and pre-clinical research. By enabling live, non-destructive, 3D, in-vivo digital imaging at the single-cell level, Optiscan's technology supports earlier disease detection, precision treatment, and improved patient outcomes across a wide selection of clinical applications and settings.

The global addressable market for Optiscan's medical imaging technology extends beyond traditional surgery and pathology, to also encompass the fast-growing digital health market including robotic surgery. With an expanding product suite and increased demand for digital health solutions, Optiscan is uniquely positioned to bridge the gap between surgery and pathology and deliver better outcomes for healthcare professionals and their patients.

To learn more about Optiscan, visit www.optiscan.com or follow us on LinkedIn, X or Instagram.

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate", "believe", "could", "estimate", "expect", "future", "intend", "may", "opportunity", "plan", "potential", "project", "seek", "will" and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.